Davis's Drug Guide
faricimab
General
Pronunciation:
far-ik-i-mab
Trade Name(s)
- Vabysmo
Ther. Class.
ocular agents
Pharm. Class.
vascular endothelial growth factor antagonists
monoclonal antibodies
temporary class
angiopoietin-2 inhibitorsThere's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., et al. "Faricimab." Davis's Drug Guide, 18th ed., F.A. Davis Company, 2023. www.drugguide.com/ddo/view/Davis-Drug-Guide/110932/all/faricimab.
Vallerand AHA, Sanoski CAC, Quiring CC. Faricimab. Davis's Drug Guide. F.A. Davis Company; 2023. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110932/all/faricimab. Accessed December 3, 2023.
Vallerand, A. H., Sanoski, C. A., & Quiring, C. (2023). Faricimab. In Davis's Drug Guide (18th ed.). F.A. Davis Company. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110932/all/faricimab
Vallerand AHA, Sanoski CAC, Quiring CC. Faricimab [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2023. [cited 2023 December 03]. Available from: https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110932/all/faricimab.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - faricimab
ID - 110932
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
AU - Quiring,Courtney,
BT - Davis's Drug Guide
UR - https://www.drugguide.com/ddo/view/Davis-Drug-Guide/110932/all/faricimab
PB - F.A. Davis Company
ET - 18
DB - Davis's Drug Guide
DP - Unbound Medicine
ER -